March 18, 2026
Unexplained hyperglycemic episodes in patients with type 1 diabetes (T1D) who are using automated insulin delivery (AID) systems may be a sign of undetected occlusions, new […]
March 17, 2026
TOPLINE: In patients with Cushing syndrome (CS) and concomitant type 2 diabetes (T2D) and/or obesity, GLP‑1 receptor agonists (GLP‑1 RAs) significantly reduced body weight and BMI […]
March 16, 2026
Pancreatic enzyme replacement therapy (PERT) — commonly used to reverse the insufficient secretion of pancreatic enzymes, or pancreatic exocrine insufficiency (PEI) — showed benefit in the […]
March 16, 2026
TOPLINE: Tight glycemic targets in women with gestational diabetes reduced the risk for large-for-gestational-age births and cesarean deliveries, without increasing the risk for serious maternal or […]
March 13, 2026
Nearly 4% of people in the US initially diagnosed with type 2 diabetes (T2D) between July 2016 and October 2024 were later reclassified as having type […]
March 13, 2026
A second-generation intraperitoneal insulin pump — the next-generation MiniMed Implantable Insulin Pump System (MIIPS 2020), which is not yet commercially licensed but can be obtained in […]
March 12, 2026
Use of tirzepatide within the first 4 years of type 2 diabetes (T2D) diagnosis produced significant improvements in glycemic control, body weight, and cardiovascular risk factors […]
March 12, 2026
TOPLINE: Among patients with schizophrenia, prediabetes, and overweight or obesity who were on stable treatment with second‑generation antipsychotics, once-weekly semaglutide led to greater improvements in insulin […]
March 11, 2026
As obesity rates continue to rise, so do pharmaceutical company investments in novel treatments. By some estimates, there were more than 160 obesity drugs in development […]